Company Overview
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology firm headquartered in Pittsburgh, Pennsylvania. The company specializes in developing gene‑therapy products for rare, debilitating disorders, with a current focus on dystrophic epidermolysis bullosa (DEB). Its flagship product, VYJUVEK (beremagene geperpavec‑svdt, or B‑VEC), is a gene therapy for DEB patients. Krystal Biotech’s market capitalization is approximately $10.1 billion, and its 2026‑08‑02 closing share price was $312.57. The company’s price‑to‑earnings ratio stands at 46.1, and it has reported a 52‑week high of $382.535 (2026‑06‑29) and a low of $132.31 (2025‑08‑06).
Q2 2026 Financial Highlights
| Item | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $119.2 million | $?? | +24 % |
| Net product revenue (VYJUVEK) | $119.2 million | $?? | +24 % |
| Gross margin | 95 % | – | – |
| Cash & investments | $1.1 billion | – | – |
| EPS | $1.85 | – | – |
Krystal Biotech announced a $119.2 million net product revenue from VYJUVEK in the second quarter of 2026, representing a 24 % increase over the same period in 2025. The product’s gross margin for the quarter was reported at 95 %. The company closed the quarter with $1.1 billion in cash and investments, reinforcing a strong balance sheet.
VYJUVEK Commercial Performance
- United States: VYJUVEK continues to perform strongly, with durable demand and broad reimbursement coverage. The company secured over 730 reimbursement approvals and expanded its prescriber base to more than 640 unique prescribers by the end of Q2 2026. Patient‑support initiatives have seen high engagement, supporting the recent label update that increases administration flexibility.
- International: The therapy has gained traction in Germany, France, and Japan, with growing physician engagement and prescription demand. Krystal Biotech is pursuing pricing and reimbursement discussions across Europe, with negotiations in Germany and France ongoing.
Pipeline and Strategic Outlook
Krystal Biotech’s pipeline is progressing toward multiple registrational studies, with data readouts expected in the second half of 2026. The company’s CEO, Krish S. Krishnan, emphasized that VYJUVEK not only changes the standard of care for DEB patients worldwide but also provides a platform for advancing high‑conviction rare‑disease programs across eye, lung, and skin indications. The company anticipates that the next 12–18 months could transition it from a commercial success story to a multi‑product genetic‑medicine company.
Market Reaction and Analyst Views
Following the earnings announcement on 2026‑08‑03, market participants noted the robust revenue growth and high gross margin. Analysts discussed the company’s valuation, citing a price‑earnings ratio of 46.1 and questioning whether the stock is overvalued given its recent earnings beat. The strong balance sheet and ongoing global expansion initiatives are viewed as positive catalysts for future growth.
Conclusion
Krystal Biotech’s Q2 2026 results demonstrate significant revenue growth driven by its flagship gene‑therapy product, VYJUVEK, and a solid financial position with ample cash reserves. Continued international expansion, a progressing pipeline, and strategic focus on rare‑disease indications position the company for potential further growth in the coming fiscal year.
